VISTA and PD-1 play non-redundant roles in regulating T cell responses, and VISTA is recognized as a potential mediator of resistance to anti-PD-1 and anti-CTLA4 immune therapies in prostate cancer patients [8]. Here, VSIR is linked to prostate carcinoma.